Tommy Thompson obviously doesn't seem to, either.
I'm sorry, but this is a major blown call. I just hope the appeal goes well.
Reading the summary of the RAND study, it is obvious that the judge blew the call:
http://www.fda.gov/bbs/topics/NEWS/ephedra/summary.html "The data on adverse events were drawn from clinical trials and case reports published in the literature, submitted to the FDA, and reported to Metabolife, a manufacturer of ephedra-containing supplement products. The strongest evidence for causality should come from clinical trials; however, in most circumstances, such trials do not enroll sufficient numbers of patients to adequately assess the possibility of rare outcomes. Such was the case with our review of ephedrine and ephedra-containing dietary supplements. Even in aggregate, the clinical trials enrolled only enough patients to detect a serious adverse event rate of at least 1.0 per 1,000. For rare outcomes, we reviewed case reports, but a causal relationship between ephedra or ephedrine use and these events cannot be assumed or proven."